Results 181 to 190 of about 424,390 (258)

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

A rare etiology of pulmonary hypertension: The scimitar syndrome. [PDF]

J Family Med Prim Care
Devalla L, Wagh PB, Ghewade B.
europepmc   +1 more source

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides

ESC Heart Failure, Volume 12, Issue 2, Page 879-887, April 2025.
Abstract Background Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF). Aims This study aimed to characterize patients with exertional dyspnoea and normal/near‐to‐normal N‐terminal pro‐brain natriuretic peptide (NT ...
Emmanuelle Berthelot, Tarek Laouar, Antoine Beurnier, Nataliya Hrynchynshyn, Jean Christophe Eicher, Jean‐Michel Tartière, Patrick Jourdain, Olivier Lairez, Barnabas Gellen   +8 more
wiley   +1 more source

Risk of bleeding in transbronchial biopsies in patients with pulmonary hypertension. [PDF]

Sci Rep
Lutz JR, Galindo JL, Barbosa V.
europepmc   +1 more source

Sotatercept for the Treatment of Myeloproliferative Neoplasm-Associated Group 5 Pulmonary Hypertension. [PDF]

JACC CardioOncol
Ali HR, Faiz SA, Deswal A, Palaskas N, Iliescu C, Thompson K, Ohanian M, Pemmaraju N, Bose P, Sahay S.   +9 more
europepmc   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Clinical research on pulmonary hypertension from a 2025 perspective: a narrative review. [PDF]

J Thorac Dis
Bai Q, Liu H, Wang H, Yao Y, Deng J, Wang T.   +5 more
europepmc   +1 more source